PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(03): 177-179
DOI: 10.4103/0971-5851.123723
ORIGINAL ARTICLE

Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur

Hemant Malhotra
Department of Medicine, Division of Medical Oncology, Birla Cancer Center, SMS Medical College Hospital, Jaipur, Rajasthan, India
,
Rajesh Sharma
Department of Medicine, Division of Medical Oncology, Birla Cancer Center, SMS Medical College Hospital, Jaipur, Rajasthan, India
,
Yogender Singh
Department of Medicine, Division of Medical Oncology, Birla Cancer Center, SMS Medical College Hospital, Jaipur, Rajasthan, India
,
Hemant Chaturvedi
Department of Medicine, Division of Medical Oncology, Birla Cancer Center, SMS Medical College Hospital, Jaipur, Rajasthan, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

This is a retrospective analysis of patients of chronic myeloid leukemia (CML) registered and under treatment at the Leukemia Lymphoma Clinic at the Birla Cancer Center, SMS Medical College Hospital, Jaipur. Approximately, two-thirds of the patients are getting imatinib mesylate (IM) through the Glivec International Patient Assistance Program while the rest are on generic IM. In addition to comparison of hematological and molecular responses in the Glivec versus the genetic group, in this analysis, an attempt is also made to assess the socio-economic (SE) status of the patients and its effect on the response rates. Of the 213 patients studied, most (28.6%) are in the age group between 30 years and 40 years and the mean age of the patients in 39 years, a good decade younger that in the west. There is a suggestion that patients in lower SE class present with higher Sokal scores and with more disease burden. Possibly hematological responses are similar with both Glivec and generic IM. No comment can be made with regards to molecular response between the two groups as a significant number of patients in the Glivec arm (42%) do not have molecular assessment because of economic reasons. CML is a common and challenging disease in the developing world with patients presenting at an earlier age with more advanced disease. SE factors play a significant role in therapy and disease monitoring decision making and may impact on response rates and prognosis.

Keywords

Chronic myeloid leukemia - chronic phase - Jaipur


Publikationsverlauf

Artikel online veröffentlicht:
19. Juli 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bhutani M, Vora A, Kumar L, Kochupillai V. Lympho-hemopoietic malignancies in India. Med Oncol 2002;19:141-50.
  • 2 Deininger MW, O′Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-47.
  • 3 Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.